Indian Drug Companies Urge Government to Stop Evergreening Tactics

Law360, New York (November 1, 2003, 12:00 AM EST) -- India's pharmaceutical companies urged the government not to reopen issues such as compulsory licensing and Bolar exception as it prepares to amend the Patent Act, the Economic Times of India reported.

These provisions were incorporated into an amendment passed last year, and it would be too early to assess their efficiency now, the industry claims.

The Indian government, which is drafting a third amendment to the act, has said the revisions would be "substantive" in nature, according to the Economic Times.

The Indian Pharmaceutical Alliance (IPA)...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.